Tunawasaidiaje wapenzi wetu wanaotoa harufu mbaya ukeni wakati wa tendo?

Mimi zamani nilikuaga najua wanawake wanaotoa shombo ni kwa sababu wanakunywa vilevi vikali. Dah kwakweli huwa different experience kabisa. Kuna mmoja nilikutana nae alikutoa harufu ya yai viza, nikawa nainua kichwa kuelekezea pua upande mwingine ila wapi. Hadi akanimaid eti anasema wewe upo mm ila kama vile humizingatii. Kumbe mwenzie shombo linanikera.

Kuna kengine nilikutana nacho kabinti kadogo, kalikua kama vile usafi wake ni mashaka kwa kukaangalia kwa nje, ila kwenda kukanyandua, waapii hakuna hata chbw ya harufu, hadi raha
 
Bacterial vaginosis (BV) is the most common cause of abnormal vaginal discharge in reproductive-age females. Treatment is aimed at relieving symptoms, although many individuals are asymptomatic. Of those with symptoms, abnormal vaginal discharge and fishy odor are typical.

Commonly associated bacteria – The major bacteria detected in females with BV are Gardnerella vaginalis, Prevotella species, Porphyromonas species, Bacteroides species, Peptostreptococcus species, Mycoplasma hominis, and Ureaplasma urealyticum, as well as Mobiluncus, Megasphaera, Sneathia, and Clostridiales species

CLINICAL FEATURES

Individuals can present with classic symptoms, symptoms that suggest multiple etiologies of vaginal discharge, or be asymptomatic.

Classic symptoms – Symptomatic individuals typically present with vaginal discharge and/or vaginal odor. The discharge is off-white, thin, and homogeneous; the odor is an unpleasant "fishy smell" that may be more noticeable after sexual intercourse and during menses

Although supporting data are limited, in our experience, in the absence of microscopy, a lack of fishy odor (negative whiff test) makes the diagnosis of BV less likely

Symptomatic patients

β€’Treatment: For nonpregnant persons with confirmed symptomatic BV, we suggest multiday treatment with metronidazole or clindamycin rather than treatment with other antibiotics. As efficacy is similar for oral or vaginal regimens of both metronidazole or clindamycin, choice of treatment route is driven by patient preference around treatment route, drug availability, and cost. Treatment of patients with a neovagina and/or HIV infection is the same.

-Preferred treatment regimens include:
Metronidazole 500 mg twice daily orally for seven days.
or
Metronidazole gel 0.75% (5 grams containing 37.5 mg metronidazole) once daily vaginally for five days.
or
Clindamycin 2% vaginal cream once daily at bedtime for seven days. During therapy with clindamycin cream, latex condoms should not be used.

-Alternate regimens – Oral tinidazole and secnidazole have demonstrated efficacy similar to oral metronidazole and convenient dosing.
 
Cookies are required to use this site. You must accept them to continue using the site. Learn more…